Unresolved Issues in the Management of AF (Joint Session)

Description

This is a session designed to revise the different management strategies for the treatment of AF. Different clinical scenarios will be discussed. Anticoagulation strategies in low-risk patients as well as for post-operative AF will be discussed. The indications for anticoagulation in the context in patients with device-detected AF will also be discussed. A joint session with CHRS/EHRA.

Learning Objectives

Review the indications for anticoagulation in the context of post-operative AF.
Revise risks and benefits of anticoagulation therapy, as well as the impact of anticoagulation therapy to prevent cognitive decline, in low-risk AF patients.
Identify the pros and cons of anticoagulation therapy for patients with device-detected AF.

Session Chair(s)

Helmut Pürerfellner, MD
Jeffrey Healey, MD

Presentation

Prevention of Cognitive Disorders in Patients with AF
Presenter(s): Lena Rivard, MD, MSci

Management of Post-operative AF
Presenter(s): William F. McIntyre, MD, PhD

Debate: Should We Anticoagulate Patients with Device-detected AF? (PRO)
Presenter(s): Emma Svennberg, MD, PhD

Debate: Should We Anticoagulate Patients with Device-detected AF? (CON)
Presenter(s): Helmut Pürerfellner, MD

Disclosures

Lena Rivard:

Nothing Relevant to Disclose

William McIntyre:

Trimedics (Honoraria/Speaking/Consulting Fee - Membership on Advisory Committees or Review Panels)
AtriCure, Inc. (Honoraria/Speaking/Consulting Fee - Membership on Advisory Committees or Review Panels)
iRhythm Technologies (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)
Trimedics Inc (Research (Contracted Grants for PIs and Named Investigators only) - Research)

Emma Svennberg:

Pfizer, Inc. (Honoraria/Speaking/Consulting Fee - Consulting)
Roche Diagnostics (Research (Contracted Grants for PIs and Named Investigators only) - Research)
Johnson and Johnson (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)

Helmut Pürerfellner:

Biosense Webster, Inc. (Honoraria/Speaking/Consulting Fee - Consulting)
Abbott (Honoraria/Speaking/Consulting Fee - Consulting)
Medtronic (Honoraria/Speaking/Consulting Fee - Consulting)
Boehringer Ingelheim (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)
Daiichi Sankyo (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)
Bristol-Myers Squibb (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)
Boston Scientific (Honoraria/Speaking/Consulting Fee - Consulting)

To view all Heart Rhythm 2025 Faculty Disclosures, please click here.

Education Framework

Supraventricular Tachyarrhythmias
-- AFib and Flutter - Anticoagulation
-- 128. Know the methods to assess risk of embolic stroke and bleeding in patients with AF using validated risk scores (such as the CHA₂DS₂-VASc score).

Summary


Availability:	No future session


Cost:	FREE


Credit Offered:	No Credit Offered